Persistent high‐risk human papillomavirus (HR‐HPV) infection is the etiological cause of virtually all cervical cancer cases. HR‐HPV screening achieved with earlier generations of HR‐HPV tests has been instrumental in the prevention and early detection of cervical cancer worldwide. The first FDA‐approved HR‐HPV test, digene Hybrid Capture 2 HPV DNA Test (HC2), has been prominent in these...
Liquid‐based cytology (LBC) has replaced the conventional Papanicolaou test in cervical cancer screening. The cervical swab specimens collected in LBC media can also be used for additional analyses including high‐risk HPV (HR‐HPV) test, DNA methylation analysis, and HPV E6/E7 mRNA test.
The stability, integrity, and recovery rate of cellular DNA and RNA after storage at different...
Financed by the National Centre for Research and Development under grant No. SP/I/1/77065/10 by the strategic scientific research and experimental development program:
SYNAT - “Interdisciplinary System for Interactive Scientific and Scientific-Technical Information”.